New drug combo shows promise in advanced lung cancer trial
NCT ID NCT07643350
First seen Jun 17, 2026 · Last updated Jun 17, 2026 · Updated 1 time
Summary
This study tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before radiation therapy can better control stage III lung cancer. About 152 adults will be randomly assigned to receive either the new combination or standard treatment. Researchers will also analyze blood and tissue samples to find markers that predict which patients benefit most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ThirdXiangyaHCSU
Changsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.